Vir Biotechnology presented new data for its chronic hepatitis D combo regimen showing sustained viral suppression and supportive safety signals, and said pivotal trials are advancing ahead of schedule. Company disclosures at a hepatology meeting indicated monthly dosing maintained low viral levels in treated patients, bolstering confidence in the program’s Phase 3 design. Vir emphasized the data strengthen the case for regulatory filings and a late‑stage run‑rate that could meaningfully expand treatment options for hepatitis D, a small but serious global disease with limited therapies. The firm plans to scale enrollment and finalize endpoints informed by the recent readouts. Competitors and public‑health stakeholders will monitor whether the regimen’s efficacy and tolerability support broad use and what manufacturing and access strategies Vir will pursue for a niche but high‑need patient population.